Moreover, recent clinical case reports have shown that the use of anti-TNF therapies in patients with rheumatological conditions and mild cases of COVID-19 prevented their further progression to the severe COVID-19 forms, most probably by mitigating deleterious effects of the high levels of TNFα and other cytokines that drive immunopathogenesis of COVID-19 [51]. This evidence concerns the gene TNF and COVID-19.